Dizal (Jiangsu) Pharmaceutical Balance Sheet Health

Financial Health criteria checks 4/6

Dizal (Jiangsu) Pharmaceutical has a total shareholder equity of CN¥23.5M and total debt of CN¥1.3B, which brings its debt-to-equity ratio to 5476.6%. Its total assets and total liabilities are CN¥1.8B and CN¥1.8B respectively.

Key information

5,476.64%

Debt to equity ratio

CN¥1.29b

Debt

Interest coverage ratio	n/a
Cash	CN¥898.76m
Equity	CN¥23.53m
Total liabilities	CN¥1.78b
Total assets	CN¥1.80b

Recent financial health updates

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Feb 17

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Aug 20

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Apr 30

Recent updates

Analysts Have Lowered Expectations For Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) After Its Latest Results

Feb 27

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Feb 17

Dizal (Jiangsu) Pharmaceutical Co., Ltd.'s (SHSE:688192) Share Price Could Signal Some Risk

Dec 24

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Aug 20

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%

May 02

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Apr 30

Financial Position Analysis

Short Term Liabilities: 688192's short term assets (CN¥1.0B) exceed its short term liabilities (CN¥893.3M).

Long Term Liabilities: 688192's short term assets (CN¥1.0B) exceed its long term liabilities (CN¥888.0M).

Debt to Equity History and Analysis

Debt Level: 688192's net debt to equity ratio (1657.7%) is considered high.

Reducing Debt: 688192's debt to equity ratio has increased from 0% to 5476.6% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 688192 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 688192 has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 15% each year.

Discover healthy companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/23 19:48
End of Day Share Price	2025/05/23 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dizal (Jiangsu) Pharmaceutical Co., Ltd. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Pei Cheng	China Galaxy Securities Co., Ltd.
Ziyu He	China International Capital Corporation Limited
Jin Zhang	China International Capital Corporation Limited

Dizal (Jiangsu) Pharmaceutical Balance Sheet Health

Financial Health criteria checks 4/6

Key information

Recent financial health updates

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Recent updates

Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences

New minor risk - Profitability

Price target increased by 12% to CN¥62.95

Consensus estimates of losses per share improve by 14%

First quarter 2025 earnings released: CN¥0.46 loss per share (vs CN¥0.54 loss in 1Q 2024)

Forecast to breakeven in 2027

Dizal to Showcase Data in Hematologic Malignancies and Lung Cancer at ASCO 2025

New minor risk - Share price stability

Dizal Announces Dzd8586 and Dzd6008 Presentations At 2025 Asco Annual Meeting

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025

Dizal Announces New Findings on Golidocitinib, A First-In-Class Janus Kinase 1 (JAK1) Only Inhibitor, in Combination with PD-1 Antibodies for Patients

Consensus revenue estimates fall by 20%

Insufficient new directors

Analysts Have Lowered Expectations For Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) After Its Latest Results

New major risk - Financial position

Full year 2024 earnings released: CN¥2.07 loss per share (vs CN¥2.72 loss in FY 2023)

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Dizal Announces U.S. Food and Drug Administration Accepts and Granted Priority Review to the Company's New Drug Application for Sunvozertinib

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Apr 30, 2025

Dizal (Jiangsu) Pharmaceutical Co., Ltd.'s (SHSE:688192) Share Price Could Signal Some Risk

Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer

Dizal Presents Latest Data of DZD8586, A Lyn/Btk Dual Inhibitor, in B-Cell Non-Hodgkin Lymphoma At the 2024 Ash Annual Meeting

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Price target increased by 7.4% to CN¥56.00

Dizal Receives Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

NMPA Approves Burning Rock and Dizal's First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dizal Announces the National Medical Products Administration of China Approves Golidocitinib for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

New minor risk - Share price stability

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Latest Data from the Inaugural Global Pivotal Study WU-KONG1 Part B (WU-KONG1B) of Sunvozertinib in Relapsed or Refractory Non-Small Cell Lung Cancer

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Consensus revenue estimates decrease by 12%

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%

New major risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

New minor risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New major risk - Revenue and earnings growth

Now 21% undervalued

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

Consensus EPS estimates fall by 13%

New major risk - Share price stability

Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients

Insufficient new directors

Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL

Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology

New major risk - Revenue and earnings growth

Dizal Will Present the Results of Molecular Analysis on EGFR Exon20ins Mutations in Tumor Tissue and Plasma ctDNA

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Compelling Data of Its Robust Oncology Portfolio At the 2023 American Society of Clinical Oncology Annual Meeting

Price target increased by 11% to CN¥56.42

Dizal Announces Center for Drug Evaluation Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations

Less than half of directors are independent

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

Dizal Demonstrates Clinical Update for Sunvozertinib (DZD9008) in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 WCLC

Dizal Pharmaceutical Announces Pre-Clinical and Clinical Results of Sunvozertinib (DZD9008) Published in Cancer Discovery

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Dizal Pharmaceutical Receives U.S. FDA Fast Track Designation for Dzd4205 for the Treatment of Refractory or Relapsed Peripheral T-Cell Lymphoma

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 (Sunvozertinib) for the Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Cash Runway Analysis